Tonix Pharmaceuticals (TNXP) Investor presentation summary

Strategic focus and financial position

• Commercial stage company addressing chronic and complex conditions with large market potential.

• $185.5M in cash and cash equivalents as of March 31, 2026, with no debt and expected runway into early Q2 2027.

• Multi-asset pipeline in CNS, infectious disease, immunology, and rare diseases.

TONMYA for fibromyalgia: launch and differentiation

• First new FDA-approved fibromyalgia treatment in over 15 years, launched November 2025.

• Sublingual, non-opioid, first-line therapy with rapid onset, robust efficacy, and durable safety profile.

• Patent protection extends to 2034, with potential exclusivity to 2044.

• Addresses dissatisfaction with current therapies; 85% of first-line treatments fail due to efficacy/tolerability.

• Over 10 million U.S. patients, but only 2.7 million diagnosed and treated annually.

Clinical evidence and safety

• Two pivotal Phase 3 studies showed statistically significant pain reduction versus placebo at 14 weeks.

• 47% of patients achieved ≥30% pain reduction versus 35% for placebo in one study.

• Most common adverse events were mild and included oral hypoesthesia and discomfort.

• No evidence of abuse potential or cognitive/sexual dysfunction.